BRPI0711646B8 - solução aquosa estéril de um sal de ácido succínico - Google Patents

solução aquosa estéril de um sal de ácido succínico

Info

Publication number
BRPI0711646B8
BRPI0711646B8 BRPI0711646A BRPI0711646A BRPI0711646B8 BR PI0711646 B8 BRPI0711646 B8 BR PI0711646B8 BR PI0711646 A BRPI0711646 A BR PI0711646A BR PI0711646 A BRPI0711646 A BR PI0711646A BR PI0711646 B8 BRPI0711646 B8 BR PI0711646B8
Authority
BR
Brazil
Prior art keywords
salt
aqueous solution
succinic acid
sterile aqueous
compound
Prior art date
Application number
BRPI0711646A
Other languages
English (en)
Inventor
S Ray Adrian
B Tumas Daniel
C Reiser Hans
S Chong Lee
A Lee William
j watkins William
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BRPI0711646A2 publication Critical patent/BRPI0711646A2/pt
Publication of BRPI0711646B1 publication Critical patent/BRPI0711646B1/pt
Publication of BRPI0711646B8 publication Critical patent/BRPI0711646B8/pt
Publication of BRPI0711646C1 publication Critical patent/BRPI0711646C1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processing Of Solid Wastes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

método e composições para tratar neoplasias malignas hematológicas. um composto de fórmula (1) e/ou seus sais, tautômeros e solvatos é usado para tratar neoplasias malignas hematológicas. em uma modalidade, um sal de ácido orgânico do composto 1 é provido para uso geral no tratamento de neoplasmas, e em uma modalidade adicional o sal é estabilizado com carboidrato.
BRPI0711646A 2006-05-16 2007-05-16 solução aquosa estéril de um sal de ácido succínico BRPI0711646C1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80098306P 2006-05-16 2006-05-16
US60/800,983 2006-05-16
US83180506P 2006-07-18 2006-07-18
US60/831,805 2006-07-18
PCT/US2007/011726 WO2007136650A2 (en) 2006-05-16 2007-05-16 Method and compositions for treating hematological malignancies

Publications (4)

Publication Number Publication Date
BRPI0711646A2 BRPI0711646A2 (pt) 2011-11-29
BRPI0711646B1 BRPI0711646B1 (pt) 2020-12-01
BRPI0711646B8 true BRPI0711646B8 (pt) 2021-04-06
BRPI0711646C1 BRPI0711646C1 (pt) 2021-05-25

Family

ID=38578698

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0711646A BRPI0711646C1 (pt) 2006-05-16 2007-05-16 solução aquosa estéril de um sal de ácido succínico

Country Status (20)

Country Link
US (3) US20090258840A1 (pt)
EP (1) EP2020996B1 (pt)
JP (2) JP5544165B2 (pt)
KR (1) KR101424832B1 (pt)
CN (1) CN101442994B (pt)
AT (1) ATE534377T1 (pt)
AU (1) AU2007254309B2 (pt)
BR (1) BRPI0711646C1 (pt)
CA (1) CA2652048C (pt)
CY (1) CY1112377T1 (pt)
DK (1) DK2020996T3 (pt)
EA (1) EA016995B1 (pt)
ES (1) ES2377467T3 (pt)
HK (1) HK1127913A1 (pt)
MX (1) MX2008014665A (pt)
NZ (1) NZ572368A (pt)
PL (1) PL2020996T3 (pt)
PT (1) PT2020996E (pt)
SI (1) SI2020996T1 (pt)
WO (1) WO2007136650A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN101437823B (zh) 2006-05-04 2014-12-10 勃林格殷格翰国际有限公司 多晶型
AU2007254309B2 (en) * 2006-05-16 2012-05-03 Gilead Sciences, Inc. Method and compositions for treating hematological malignancies
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP2731947B1 (en) 2011-07-15 2019-01-16 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
US11186599B2 (en) * 2018-06-12 2021-11-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Phosphonamide ester compound, salt thereof, related crystal form thereof, preparation method therefor and use thereof
CN112168829B (zh) * 2020-09-24 2022-02-15 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
CA2416757C (en) 2000-07-21 2011-02-15 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
SI1360169T1 (sl) * 2001-02-12 2007-12-31 Wyeth Corp Sukcinatna sol o-desmetil-venlafaksina
CA2468705A1 (en) * 2001-11-29 2003-06-05 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
CA2469889A1 (en) * 2001-12-12 2003-06-19 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
JP4476811B2 (ja) * 2002-05-13 2010-06-09 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびそのアナログの新規ホスホン酸系プロドラッグ
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
MXPA06001938A (es) * 2003-08-18 2006-05-17 Lundbeck & Co As H Trans-1-(6-cloro-3-fenilindan-1-il)-3,3-dimetilpiperazina.
PT2204374E (pt) * 2003-12-30 2012-09-17 Gilead Sciences Inc Fosfonatos nucleosídeos e seus análogos para o tratamento de infecções com hpv
ATE445404T1 (de) 2004-01-21 2009-10-15 Gilead Sciences Inc Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
AR058361A1 (es) * 2005-12-16 2008-01-30 Wyeth Corp Composiciones lifolizadas de un compuesto de triazolopirimidina
AU2007254309B2 (en) * 2006-05-16 2012-05-03 Gilead Sciences, Inc. Method and compositions for treating hematological malignancies

Also Published As

Publication number Publication date
KR20090015122A (ko) 2009-02-11
NZ572368A (en) 2011-04-29
ES2377467T3 (es) 2012-03-27
AU2007254309A1 (en) 2007-11-29
PT2020996E (pt) 2012-02-20
CN101442994A (zh) 2009-05-27
CY1112377T1 (el) 2015-12-09
US20090258840A1 (en) 2009-10-15
US20110172192A1 (en) 2011-07-14
US20080039427A1 (en) 2008-02-14
KR101424832B1 (ko) 2014-08-06
EA016995B1 (ru) 2012-09-28
WO2007136650A3 (en) 2008-01-24
BRPI0711646C1 (pt) 2021-05-25
US8435969B2 (en) 2013-05-07
EP2020996B1 (en) 2011-11-23
MX2008014665A (es) 2008-11-28
PL2020996T3 (pl) 2012-04-30
WO2007136650A2 (en) 2007-11-29
AU2007254309B2 (en) 2012-05-03
SI2020996T1 (sl) 2012-03-30
DK2020996T3 (da) 2012-02-27
CA2652048A1 (en) 2007-11-29
HK1127913A1 (en) 2009-10-09
EP2020996A2 (en) 2009-02-11
CN101442994B (zh) 2013-03-06
CA2652048C (en) 2012-12-11
BRPI0711646A2 (pt) 2011-11-29
JP5544165B2 (ja) 2014-07-09
JP2013100324A (ja) 2013-05-23
EA200802333A1 (ru) 2009-04-28
ATE534377T1 (de) 2011-12-15
JP2009537539A (ja) 2009-10-29
BRPI0711646B1 (pt) 2020-12-01

Similar Documents

Publication Publication Date Title
BRPI0711646B8 (pt) solução aquosa estéril de um sal de ácido succínico
PE20090770A1 (es) Derivados de benzoxazolona
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
EA200801630A1 (ru) Соединения пиперазина с гербицидным действием
BR112015009850A2 (pt) compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
CY1111721T1 (el) Ακυλαμινοπυραζολια ως αναστολεις fgfr
BRPI0713378A8 (pt) composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto
BRPI0621386B8 (pt) composição farmacêutica para o uso externo
BR112012020311A2 (pt) &#34;compostos, medicamento, método para inibir um ciclo de divisão celular, método para a profilaxia ou tratamento de câncer, e, uso do composto.&#34;
NI201100223A (es) Derivados de imidazolidina 2 -0ne 1,3 - disustituidos como inhibidores de cyp 17
NO20065416L (no) Hemming av fremstillingen av biogene sulfider via kombinasjoner av biocide og metabolske inhibitorer
ECSP099330A (es) Compuesto de indol
CY1117659T1 (el) Υδατικο διαλυμα που περιλαμβανει 3-κινουκλιδινονες για τη θεραπεια υπερπλαστικης, αυτοανοσης και καρδιακης ασθενειας
ECSP11011165A (es) Compuesto heterocíclico y uso del mismo
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
ECSP099073A (es) Nuevos derivados de piridazina
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
BRPI0706966A8 (pt) Composição para um efeito microbicida em um sistema de água, método para estabilizar cloro para ser utilizado como um biocida no tratamento de água em um sistema de processamento, e método para tratar um sistema de água de processamento de papel
BR112013028598A2 (pt) método para promover o crescimento de plantas
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CL2011001026A1 (es) Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato.
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
BR112012033599A2 (pt) novos derivados de tetrahidroquinolina.
BRPI0713743B8 (pt) composto, e, composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2604 DE 01/12/2020 QUANTO AO ENDRECO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/05/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF